Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

89 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Double-blind, multicenter, randomized trial to compare the effect of two doses of adrenocorticotropic hormone versus placebo in controlling delayed emesis after high-dose cisplatin in adult patients with cancer.
Passalacqua R, Cocconi G, Caminiti C, Silingardi V, Bella MA, Bichisao E, Michiara M, Malavasi V, Donati D, Di Costanzo F, Rocca A, Di Sarra S, Scaglione F, Fraschini F. Passalacqua R, et al. Among authors: caminiti c. J Clin Oncol. 1997 Jun;15(6):2467-73. doi: 10.1200/JCO.1997.15.6.2467. J Clin Oncol. 1997. PMID: 9196163 Clinical Trial.
[Guidelines for psychosocial care of cancer patients].
Associazione Italiana di Oncologia Medica; Caminiti C. Associazione Italiana di Oncologia Medica, et al. Among authors: caminiti c. Assist Inferm Ric. 2013 Oct-Dec;32(4):233-8. doi: 10.1702/1381.15361. Assist Inferm Ric. 2013. PMID: 24441468 Italian.
Patients' opinions, feelings, and attitudes after a campaign to promote the Di Bella therapy.
Passalacqua R, Campione F, Caminiti C, Salvagni S, Barilli A, Bella M, Barni S, Barsanti G, Caffo O, Carlini P, Cinquemani G, Di Costanzo F, Giustini L, Labianca R, Mazzei A, Olmeo N, Paccagnella A, Toscano L, Cocconi G. Passalacqua R, et al. Among authors: caminiti c. Lancet. 1999 Apr 17;353(9161):1310-4. doi: 10.1016/S0140-6736(98)10253-2. Lancet. 1999. PMID: 10218529
Prospective, multicenter, randomized trial of a new organizational modality for providing information and support to cancer patients.
Passalacqua R, Caminiti C, Campione F, Diodati F, Todeschini R, Bisagni G, Labianca R, Dalla Chiesa M, Bracci R, Aragona M, Artioli F, Cavanna L, Masina A, De Falco F, Marzocchini B, Iacono C, Contu A, Di Costanzo F, Bertetto O, Annunziata MA. Passalacqua R, et al. Among authors: caminiti c. J Clin Oncol. 2009 Apr 10;27(11):1794-9. doi: 10.1200/JCO.2007.15.0615. Epub 2009 Mar 9. J Clin Oncol. 2009. PMID: 19273715 Clinical Trial.
Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M, Buti S, Lazzarelli S, Bozzetti R, Rivoltini L, Camisaschi C, Castelli C, Bearz A, Simonelli C, Lo Re G, Mattioli R, Caminiti C, Passalacqua R; GOIRC (Italian Oncology Group for Clinical Research). Donini M, et al. Among authors: caminiti c. Target Oncol. 2015 Jun;10(2):277-86. doi: 10.1007/s11523-014-0337-6. Epub 2014 Sep 19. Target Oncol. 2015. PMID: 25230695 Clinical Trial.
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer.
Passalacqua R, Buzio C, Buti S, Porta C, Labianca R, Pezzuolo D, Camisa R, Sabbatini R, Benecchi L, Messina C, Cengarle R, Vaglio A, Dalla Chiesa M, Tomasello G, Caminiti C. Passalacqua R, et al. Among authors: caminiti c. Cancer Immunol Immunother. 2010 Apr;59(4):553-61. doi: 10.1007/s00262-009-0773-9. Epub 2009 Sep 25. Cancer Immunol Immunother. 2010. PMID: 19779715 Free PMC article. Clinical Trial.
89 results